A 69-year-old male patient with lung adenocarcinoma was treated with nivolumab for 18 cycles, and then replaced with camrelizumab for 3 cycles. One month after the last treatment, he developed white plaques on the face, the back of hands and the lower limbs, and diagnosed as vitiligo. The patient continued immunotherapy with camrelizumab, and regular CT scan indicated disease stable without further expansion of vitiligo lesions. This case suggested that vitiligo may also develop in non-melanoma patients during treatment with PD-1/PD-L1 inhibitors.